OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 23, 2015 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (NASDAQ:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that it has been included in Deloitte’s 2015 Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Oxford Immunotec was ranked 251st in the list of 500, based upon Deloitte’s assessment that the Company grew annual revenue 292 percent during this period.
“The Company is honored to be included among such prestigious technology companies. This recognition is a direct reflection of the diligent efforts of all the members of the Oxford Immunotec team,” said Peter Wrighton-Smith Ph.D., Chief Executive Officer of Oxford Immunotec. “Our growth in recent years can be attributed to the successful global commercialization of our T-SPOT platform, which allows for the examination of immune responses on a single cell level. Our T-SPOT.TB test has improved the diagnosis of tuberculosis infection around the world and we continue to leverage our technology in the development of innovative diagnostic tests for other immune-regulated conditions including chronic infections, transplantation, autoimmune and inflammatory disease and immune-oncology.”
“Amid a fierce business climate, there appears to be no shortage of new and established companies that are unlocking growth and advancement through the continued disruption and proliferation of innovation,” said Sandra Shirai, principal, Deloitte Consulting LLP and U.S. technology, media and telecommunications leader. “It is inspiring to witness the dynamic ways that companies are incorporating emerging technologies for business gains in medical device, pharmaceuticals or diagnostic testing. We congratulate all those ranked on this year’s Fast 500 and look forward to seeing their continued growth into 2016.”
About Deloitte’s 2015 Technology Fast 500™
Deloitte’s Technology Fast 500 provides a ranking of the fastest growing technology, media, telecommunications, life sciences and energy tech companies – both public and private – in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2011 to 2014.
In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company's operating revenues. Companies must have base-year operating revenues of at least $50,000 USD or CD, and current-year operating revenues of at least $5 million USD or CD. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The Company’s first product is the T-SPOT.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The T-SPOT.CMV test is the Company’s second product and the first in a series of products intended for the transplantation market. Overall, the Company has seven active development programs, each of which leverages our T cell, B cell and innate immune measuring technology. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
For Media Inquiries:
Tel: +44 1235 442796
For Investor Inquiries:
Chief Financial Officer
Tel: +1 (508) 573-9953
Tel: +1 (443) 213-0500
Source: Oxford Immunotec